Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity-Reference-Cited by-同舟云学术

Revisiting an IgG Fc Loss-of-Function Experiment: the Role of Complement in HIV Broadly Neutralizing Antibody b12 Activity

Published:2021-10-26 Issue:5 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Goldberg Benjamin S.¹,Kaku Chengzi I.¹,Dufloo Jérémy²,Bruel Timothée²,Schwartz Olivier²,Spencer David A.³,Hessell Ann J.³,Ackerman Margaret E.¹⁴^ORCID

Affiliation:

1. Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire, USA

2. Virus and Immunity Unit, Department of Virology, Institut Pasteur, Paris, France

3. Division of Pathobiology and Immunology, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA

4. Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, USA

Abstract

Given the suboptimal outcome of VRC01 antibody-mediated prevention of HIV-1 infection in its first field trial, means to improve diverse antiviral activities in vivo have renewed importance. This work revisits a loss-of-function experiment that investigated the mechanism of action of b12, a similar antibody, and finds that the reason why complement-mediated antiviral activities were not observed to contribute to protection may be the inherent lack of activity of wild-type b12, raising the prospect that this mechanism may contribute in the context of other HIV-specific antibodies.

Funder

HHS | National Institutes of Health

Fondation pour la Recherche Médicale

Agence Nationale de Recherches sur le Sida et les Hépatites Virales

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.01743-21

Reference66 articles.

1. Antibody therapies for the prevention and treatment of viral infections

2. Hinton DM. 2021. Emergency use authorization 094. US Department of Health and Human Services, Washington, DC.

3. Hinton DM. 2020. Emergency use authorization letter: response to Regeneron Pharmaceutical, Inc’s (“Regeneron”) request. US Food and Drug Administration, Silver Spring, MD.

4. Hinton DM. 2021. Emergency use authorization 094. US Food and Drug Administration, Silver Spring, MD.

5. Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D;Cell Reports Medicine;2024-02

2. Antibody effector functions are required for broad and potent protection of neonates from herpes simplex virus infection;2023-08-31

3. Polyfunctionality of broadly neutralizing HIV-1 antibodies;Current Opinion in HIV and AIDS;2023-05-09

4. Complement contributes to antibody-mediated protection against repeated SHIV challenge;Proceedings of the National Academy of Sciences;2023-05-08

5. Antiviral neutralizing antibodies: from in vitro to in vivo activity;Nature Reviews Immunology;2023-04-17